MiNA Therapeutics Appoints Peter Bains as Chief Business Officer 29 September, 2020 MiNA Therapeutics Secures £23 Million Series A Financing to Advance First-in-Class Activating RNA-Based Therapeutics 10 September, 2020 MiNA Therapeutics Presents Top Line Results from Phase Ib Study of MTL-CEBPA in Combination with Sorafenib in Liver Cancer at 2020 ASCO Annual Meeting 29 May, 2020 MiNA Therapeutics Announces Publication of Phase I Liver Cancer Data in Clinical Cancer Research and Provides Update on Clinical Development and Drug Discovery Programs 27 May, 2020


Harnessing the innate mechanism of gene activation, MiNA Therapeutics’ platform enables the development of new medicines that restore normal function to patients’ cells. We are applying our technology and clinical know-how to transform the therapy landscape of cancer and other severe diseases.


Small activating RNAs are an entirely new class of medicines with potential to offer transformational benefits to patients across a wide range of diseases.


We have developed a systematic approach to take new saRNA medicines from an idea to patients in a clinical trial in just 2 years.


Driving our platform are a group of passionate scientists, drug developers, doctors and entrepreneurs shaped by experience in oligonucleotide therapeutics, oncology and immunology.

By continuing to use this site you are agreeing only to the use of cookies that are strictly necessary for the running of our website. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.